Background Men with high serum prostate specifi c antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-eff ects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy.
Introduction
The diagnosis of prostate cancer diff ers from that in other solid organ cancers where imaging is used to identify those patients who require a biopsy. The prostate cancer diagnostic pathway off ers transrectal ultrasoundguided biopsy (TRUS-biopsy) in men who present with an elevated serum prostate specifi c antigen (PSA). As a result, many men without cancer undergo unnecessary biopsies, clinically insignifi cant cancers are often detected and clinically signifi cant cancers are sometimes missed.
1,2 TRUS-biopsy also carries signifi cant morbidity and can cause life-threatening sepsis. 3 A pathway with imaging as a triage test to decide which men with an elevated PSA go on to biopsy might both reduce unnecessary biopsy and improve diagnostic accuracy. Multi-Parametric Magnetic Resonance Imaging (MP-MRI) provides information on not just tissue anatomy but also tissue characteristics such as prostate volume, cellularity, and vascularity. There is some evidence that MP-MRI tends to detect higher risk disease and systematically overlooks low-risk disease, 4 ,5 which makes it attractive as a potential triage test. 6, 7 In our study, we aimed to investigate whether MP-MRI could discriminate between men with and without clinically signifi cant prostate cancer based on template prostate mapping biopsy (TPM-biopsy) as a reference test. TPM-biopsy is able to accurately characterise disease status in men at risk by sampling the entire prostate every 5 mm. We also aimed to compare the accuracy of MP-MRI with that of TRUS-biopsy. 8 We hypothesised that MP-MRI could be used as a triage test to decide which men with an elevated PSA might safely avoid immediate biopsy. 9 
Methods
PROMIS was a prospective, multi-centre, paired-cohort, confi rmatory study, which represented level 1b evidence for diagnostic test assessment 10 and reported to the Standards for Reporting Diagnostic Accuracy. 11 Men were eligible if they had a clinical suspicion of prostate cancer with no previous prostate biopsy. The conduct and reporting of each test was done blind to the other test results. The full details of our protocol can be accessed at http://www.ctu.mrc.ac.uk/our_research/research_areas/ cancer/studies/promis/. 8 Ethics committee approval was granted by National Research Ethics Service Committee London (reference 11/LO/0185).
Our primary objectives were to establish the proportion of men who could safely avoid biopsy and the proportion of men correctly identifi ed by MP-MRI to have clinically signifi cant prostate cancer. We also carried out a head-tohead comparison of the accuracy of TRUS-biopsy and MP-MRI in terms of sensitivity, specifi city, positive predictive value and negative predictive value or clinically signifi cant prostate cancer, using TPM-biopsy as the reference standard. TPM-biopsy was chosen as the reference test because it samples the entire prostate, is highly accurate with estimated 95% sensitivity for clinically signifi cant prostate cancers due to its 5 mm sampling frame. Third, the test can minimise selection and work-up biases because it can be applied to men at risk who have had no previous biopsy (appendix fi gure S1).
Patients
Men who had never had a prostate biopsy were eligible if there was clinical suspicion they might have prostate cancer and they had been advised to have a prostate biopsy. This included men with an elevated serum PSA (up to 15 ng/mL) within previous 3 months, suspicious digital rectal examination, suspected organ confi ned stage T2 or lower on rectal examination, or family history. Eligible men were aged at least 18 years, fi t for general or spinal anaesthesia, and fi t to undergo all protocol procedures including a transrectal ultrasound. Men were required to give written informed consent. Patients were excluded if they were using 5-alpha-reductase inhibitors at time of registration or during the previous 6 months; had previous history of prostate biopsy, prostate surgery, or treatment for prostate cancer (interventions for benign prostatic hyperplasia or bladder outfl ow obstruction were acceptable); had evidence of a urinary tract infection or history of acute prostatitis within the last 3 months; had any contraindication to MRI (eg, claustrophobia, pacemaker, estimated glomerular fi ltration rate ≤50); had any other medical condition precluding procedures
Research in context
Evidence before this study Men with an elevated serum PSA blood test usually undergo transrectal ultrasound guided (TRUS) biopsy. TRUS-biopsy is blind to the location of cancer in the prostate, leading to many men without clinically important cancers undergoing unnecessary biopsy, over diagnosis of clinically unimportant disease, and under-diagnosis of clinically important cancers. In PROTECT, men diagnosed with prostate cancer as a result of PSA screening were randomly assigned to active monitoring, radical prostatectomy, or radical radiotherapy. Results of the study showed no cancer-specifi c survival diff erences at a median of 10 years follow-up but reduced time to metastases with treatment. Over three-quarters of men in PROTECT had low risk disease, exemplifying the problem of over-diagnosis from a TRUS biopsy in all strategy and the need to avoid biopsy in such men whilst improving detection of cancer that requires treatment. A systematic review found multi parametric magnetic resonance imaging (MP-MRI) had sensitivity 58-96% and negative predictive value of 63-98% with specifi city 23-87%.
MP-MRI has not been assessed using an appropriate reference standard. Previous studies have either used TRUS-biopsy or radical prostatectomy specimens as the reference standard. TRUS-biopsy is inaccurate and radical prostatectomy specimens are highly selected since men must test positive for cancer on TRUS-biopsy and choose to have surgery so these previous estimates of diagnostic accuracy are potentially inaccurate.
Added value of this study
We assessed the diagnostic accuracy of TRUS-biopsy and MP-MRI using transperineal template prostate mapping biopsies (TPM-biopsies) as the reference standard. TPM-biopsies can be applied to men at risk and are highly accurate since the prostate is sampled every 5 mm. PROMIS shows that MP-MRI has signifi cantly better sensitivity and negative predictive value for clinically important prostate cancer compared with TRUS-biopsy. Thus, MP-MRI could be used as a triage test before fi rst biopsy to allow one quarter of men at risk to avoid biopsy. The lower specifi city and positive predictive value of MP-MRI means that a biopsy is still required with a suspicious MP-MRI. Men with suspicious MP-MRI areas can have biopsies guided by these fi ndings. Overall, this strategy could improve detection of clinically important prostate cancer and reduce the number of men diagnosed with clinically unimportant disease.
Implications of all the available evidence MP-MRI should be used as a triage test before prostate biopsy in men who present with an elevated serum PSA. described in the protocol; or had previous history of hip replacement surgery, metallic hip replacement, or extensive pelvic orthopaedic metal work.
Procedures

Test 1: MP-MRI (index test)
Patients received a standardised MP-MRI, compliant with European Society of Uro-Radiology guidelines, with 1·5 Tesla magnetic fi eld strength and a pelvic phased-array coil. T1-weighted, T2-weighted, diff usion-weighted and dynamic gadolinium contrast-enhanced imaging sequences were acquired (appendix table S1). The protocol allowed men to be withdrawn after the MP-MRI scan if there was evidence of T4 disease or if the prostate volume was greater than 100 mL as TPM-biopsy could not be applied fully to such large prostates. All MRI scanners used by sites and individual MP-MRI scans underwent quality control checks by an independent commercial imaging Clinical Research Organization appointed through open tender (Ixico Ltd, London, UK). Scans deemed of insuffi cient quality were repeated before the biopsy.
MP-MRI scans were reported at each centre by dedicated urologic radiologists who had previous experience of reporting prostate MP-MRI. They also underwent centralised training involving an initial whole day course, in which 20-30 cases were reviewed individually, scored, and then reviewed as a group. A further training day occurred after the pilot phase with further 20-30 cases reviewed individually and collectively. Radiologists were provided with clinical details including PSA, digital rectal examination fi ndings, and any other risk factors such as family history. A 5-point Likert radiology reporting scale was used to designate prostates as highly unlikely (1), unlikely (2), equivocal (3), likely (4), and highly likely (5) to harbour clinically signifi cant prostate cancer. An MP-MRI score of 3 or greater designated a suspicious scan for the purpose of our primary outcomes. This scoring system was based on the outputs of a consensus group 12 convened before the publishing of the Prostate Imaging and Data Reporting System (PIRADS) MP-MRI reporting consensus. 13 Subsequent comparisons of the Likert and PIRADS reporting schemes have yielded similar results. 14, 15 To assess inter-observer agreement, 132 scans from the lead site were re-reported by a blinded second radiologist based at that site.
Tests 2 and 3: combined biopsy procedure
Once the MP-MRI report had been deposited at the central trial offi ce, a combined prostate biopsy procedure was done under general or spinal anaesthesia. Patients and physicians remained blinded to the MP-MRI images and report. Patients fi rst underwent a TPM-biopsy 16, 17 followed by TRUS-biopsy. We combined TPM-biopsy with TRUS-biopsy under the same procedure to reduce patient visits and minimise dropout between tests. Due to ethics committee concerns, TRUS-biopsy was done after the TPM-biopsy to minimise infection risk. The independent Trial Steering Committee monitored safety of this combined procedure in terms of sepsis and other important side-eff ects, and no concerns were raised during the trial.
The reference test (TPM-biopsy) was done with core biopsies taken every 5 mm and centrally reported at the lead centre (UCLH) by one of two expert uropathologists blinded to all MR images and TRUS-biopsy fi ndings.
In the standard test (TRUS-biopsy), 10-12 core biopsies were taken as per international standards, 18 with each core identifi ed and processed separately. The TRUSbiopsy samples were reported by expert uropathologists at each site blinded to the all MR images and TRUSbiopsy fi ndings.
Defi nition of clinically signifi cant prostate cancer
Disease signifi cance was defi ned by criteria previously developed and validated for use with TPM-biopsy for detection of primary Gleason grade 4 or greater 19 and cancer core length predictive for the presence of lesions 0·5 mL or larger. [20] [21] [22] [23] Gleason scoring was based on the most frequent pattern and not the highest grade detected on histological analysis. The primary defi nition used a histological target condition on TPM-biopsy that incorporated the presence of Gleason ≥4 + 3 or more, or a maximum cancer core length (MCCL) involvement of 6 mm or more in any location. Other defi nitions of clinical signifi cance were also assessed secondarily.
Sample size
Power calculations were done in relation to precision around the estimates for MP-MRI accuracy in terms of the joint primary outcomes of sensitivity and specifi city, a head-to-head comparison of MP-MRI versus TRUSbiopsy, and an assumed underlying prevalence of primary defi nition clinically signifi cant cancer of 15%. All calculations were based on 90% power and 5% signifi cance (2-sided). This generated a minimum target of 321 (for strong correlation between the tests) and maximum 714 men (for no correlation between the tests).
The Independent Trial Steering Committee carried out an a-priori interim review after 50 men had undergone all 3 tests, and although a higher than anticipated prevalence of any cancer was observed at that time, no changes were recommended to the target sample size.
Statistical analysis
Our sample size target was 714 men. All statistical analyses were done according to a statistical analysis plan agreed before inspection of the data. All analyses were done using Stata version 13.0 software (Stata Corporation, College Station, TX, USA). For each comparison, 2 × 2 contingency tables were used to present the results and calculate the diagnostic accuracy estimates with 95% confi dence intervals. The unit of assessment for our 2 × 2 contingency table for assessment of accuracy was one patient (ie, the whole prostate). The statistical analysis plan pre-specifi ed that TPM-biopsy results would take precedence over TRUS-biopsy results even if TRUS-biopsy detected clinically signifi cant cancers that TPM-biopsy missed.
Given the paired nature of the test results, McNemar tests were used for the head-to-head comparisons of sensitivity and specifi city between MP-MRI and TRUSbiopsy. Given that the positive and negative predictive values are dependent on prevalence of disease, a general estimating equation (GEE) logistic regression model was used to compare the positive predictive value and negative predictive value for MP-MRI and TRUS-biopsy against TPM-biopsy. 24, 25 Odds ratios represent the odds of each test correctly detecting the presence or absence of disease. For specifi city and negative predictive value, the coding logic is reversed as the correct test result is a negative test result. Ratios are presented as TRUS relative to MP-MRI so ratios greater than 1 favour TRUS and ratios less than 1 favour MP-MRI. LCB had full access to the data and HUA had responsibility for submission of the manuscript.
Results
Between May 17, 2012, and Nov 9, 2015, 740 men were recruited and registered across 11 centres (fi gure 1). A total of 576 men underwent all 3 tests with 164 withdrawn for various reasons (appendix table S2). Baseline characteristics for all men (both included and withdrawn) are presented in appendix table S3. The median time between MP-MRI and combined biopsy was 38 days (IQR 1-111) days.
Cancer was detected on TPM-biopsy in 408 (71%) of 576 men (95% CI 67-75%). The prevalence of clinically signifi cant cancer according to the primary defi nition was 230 (40%) of 576 men (36) (37) (38) (39) (40) (41) (42) (43) (44) . Gleason score ≥4 + 3 occurred in 56 (10%) of 576 men (7) (8) (9) (10) (11) (12) and Gleason ≥3 + 4 or greater 220 (38%) of 576 (34) (35) (36) (37) (38) (39) (40) (41) (42) . 174 men were classifi ed as signifi cant on the basis of core length despite having low grade disease (appendix table S4). Data collection was more than 95% complete. For 13 men, clinically signifi cant cancer was detected on TRUS-biopsy but missed on TPM. The statistical analysis plan specifi ed that the TPM-biopsy results should take precedence so in 13 (2%) of 576 men in whom TRUS-biopsy designated a patient as having clinically signifi cant cancer, these were treated as false positives as TPM-biopsy found no cancer or clinically insignifi cant cancer.
Figures 2 and 3 present the diagnostic results for sensitivity, specifi city, positive predictive value and negative predictive value for MP-MRI and TRUS-biopsy against TPM-biopsy. Appendix fi gure S2 presents the proportion of clinically signifi cant disease within each MP-MRI score.
Sensitivity of MP-MRI for clinically signifi cant cancer was 93% (95% CI 88-96%) and negative predictive value 89% (83-94%). Specifi city of MP-MRI was 41% (36-46%) with positive predictive value 51% (46-56%). 158 (27%) of 576 men had a negative MP-MRI, of whom 17 had clinically signifi cant cancer on TPM-biopsy (fi gure 2). All 17 men had Gleason grade 3 + 4 or less with core lengths that ranged from 6-12 mm (appendix We considered the implications of using MP-MRI by comparing the standard strategy of TRUS-biopsy for all men to two alternative strategies using MP-MRI as a triage test where only men with a suspicious MP-MRI (Likert score ≥3) would go on to biopsy (appendix table S6). Under the worst case scenario, a standard TRUS-biopsy would be done. Under the best case scenario, the biopsies would be guided by the MP-MRI fi ndings and results are presented assuming targeted biopsies would achieve similar diagnostic accuracy as TPM-biopsy. 26, 27 For both these scenarios, 158 (27%) of 576 men would avoid a primary biopsy. For the worst case scenario, an absolute reduction in the over-diagnosis of clinically insignifi cant cancers might be seen, of 28 (5%) fewer cases per 576 men (relative reduction of 31%, 95% CI 22-42%). For the best case scenario, overdiagnosis of clinically insignifi cant cancer might be increased to 21%, ie, 31 (5%) more cases per 576 men. For the correct diagnosis of clinically signifi cant cancer, the best case scenario might lead to 102 (18%) more cases of clinically signifi cant cancer being detected per 576 men compared with the standard pathway of TRUS-biopsy for all (table S6). As we did not test MRI targeted TRUS biopsy, the actual eff ect of including MP-MRI into the pathway probably lies somewhere between these best and worst case scenarios.
We also evaluated the diagnostic accuracy of TRUSbiopsy and MP-MRI for other defi nitions of clinical signifi cance on TPM-biopsy. The second defi nition we used was Gleason ≥3 + 4 or any grade with cancer core length 4 mm or greater. We also evaluated diagnostic accuracy for the presence of any Gleason score 7 (≥3 + 4) prostate cancer. The results for all 3 defi nitions are presented in the table and despite quite diff erent prevalence of disease, the performance of the diagnostic tests did not alter markedly. Clinically signifi cant cases missed under these defi nitions are presented in appendix tables S5 and S7.
For the 132 men who had blinded, double reporting of their MP-MRI scans, agreement for detection of clinically signifi cant cancer (primary defi nition) according to the dichotomisation of the MP-MRI scores (1-2 as negative, 3-5 as positive) was 80% (95% CI 72-87%, appendix 
Discussion
PROMIS is the fi rst study to our knowledge that presents blinded data on the diagnostic accuracy of both MP-MRI and TRUS-biopsy against an accurate reference test in biopsy-naive men with a suspicion of prostate cancer. It is the largest registered trial to date of the population at risk, across many centres and in which the conduct and reporting of each test was standardised and done blind to the other test results. 28, 29 PROMIS represents level 1b evidence for assessment of diagnostic accuracy. The main fi ndings suggest that if MP-MRI was used as a triage test, one-quarter of men might safely avoid prostate biopsy. The high negative predictive value is reassuring in that a negative MP-MRI result implies a high probability of no clinically signifi cant cancer. Further, over-diagnosis of clinically insignifi cant cancers might be reduced while detection of clinically signifi cant cancers improved compared with the standard of TRUS-biopsy for all men. The lower specifi city and positive predictive value of MP-MRI shows that a biopsy, with the needles deployed based on the MP-MRI fi ndings, is still needed in those men with a suspicious MP-MRI.
Our results support the fi ndings of systematic reviews that assess the diagnostic accuracy of MP-MRI. 30, 31 The reviews declared sensitivities of 58-96%, negative predictive value of 63-98% and specifi city of 23-87%. The ranges were broad because of the single centre nature of the studies, each of which invoked diff erent target conditions on diff erent reference standards. Most studies were limited by retrospective analysis, non-blinding of imaging fi ndings (incorporation and reporting biases), and MP-MRI comparison with inaccurate (TRUS-biopsy) or inappropriate (radical prostatectomy) reference tests. One other prospective study compared MP-MRI with TPM-biopsy that reported interim 32 and then fi nal results. 33 This study reported 96% sensitivity, 36% specifi city, 92% negative predictive value and 52% positive predictive value for detection of clinically signifi cant cancer (defi ned as Gleason score 7-10 with more than 5% Gleason grade 4, 20% or more positive cores, or 7 mm or larger tumour). This Australian study was not blinded, was single-centre, permitted two magnetic fi eld strength scanners (1·5 Tesla or 3·0 Tesla), used a TPM-biopsy protocol that sampled the prostate with fewer cores and did not include the standard test, TRUS-biopsy. 34 Our study has some limitations. First, although the use of a 5 mm sampling frame of the entire prostate, while too invasive for routine clinical use, off ered the precision required for a highly accurate reference test by virtue of its uniform sampling density over the entire prostate gland, this did mean prostates over 100 mL had to be excluded due to template grid size and bony pubic arch interference. 35 Exclusion of large prostates might result in a decrease in the proportion of true negatives within PROMIS. Second, we acknowledge that PROMIS represents a selected group although it is encouraging that men who were subsequently withdrawn from the study did not diff er from those who completed the study. Third, the sequence of TPM-biopsy followed by TRUSbiopsy might have contributed to the poor accuracy of the standard test due to swelling, distortion, and tissue disruption. The sequencing was based on patient safety and to preserve the integrity of the reference test. Fourth, by the need for blinding, we did not have targeting of MR-suspicious lesions and cannot accurately assess clinical utility of a MR-targeted biopsy approach. Fifth, although we included some measurement of interobserver variability, these were between two expert readers. Further work is required to measure the interobserver variability of expert and non-expert reporters. Last, we acknowledge that likelihood ratios and area under the receiver operating characteristic curves were not part of the pre-specifi ed analysis plan. These metrics provide an overall measure of test performance and clarify the relative strengths and weaknesses of each test, particularly as likelihood ratios are independent of disease prevalence.
The MP-MRI scans in PROMIS were done using 1·5 Tesla magnetic fi eld strength. This was chosen because of its wide availability, and on the assumption that, if benefi t was shown, then it was likely to be at least maintained at higher magnetic fi eld strengths where greater signal-to-noise ratios can be achieved.
PROMIS was intentionally designed to be done in multiple sites and it was reassuring that analysis of the results stratifi ed between the central training site (UCLH) and non-UCLH sites reported almost identical fi ndings. Of note in PROMIS, the inter-observer agreement results indicate that there was moderate agreement of MP-MRI scores between two independent radiologists. Our results show that variation usually occurred by 1 point on the Likert scale. Nonetheless, this is an important consideration and highlights the necessity for a robust training programme for radiologists. We have shown that a high quality MP-MRI can be delivered in a multicentre setting in the UK NHS, but all health-care settings will need to consider the capacity issues around access to high-quality MP-MRI, high quality reporting and high quality MRI-targeted biopsies.
Studies using TPM-biopsy as the primary biopsy have previously reported a high prevalence of clinically signifi cant disease. 23, 36 This highlights the uncertainty around what constitutes clinical signifi cance. 37 In healthcare systems with higher rates of previous PSA testing, the proportion of men with clinically signifi cant prostate cancer, as we have defi ned it, is likely to be lower. If MP-MRI were used as a triage test in these settings, then the number of men who could potentially avoid a primary biopsy might be higher. Further, the recent ProtecT trial demonstrates no cancer-specifi c survival benefi t over active monitoring when men are treated with radical prostatectomy or radical radiotherapy, although there was a benefi cial eff ect in reducing time to metastases. 38 With the majority of patients having low risk disease in PROTECT, this adds weight to the need for strategies, such as MP-MRI, that reduce the diagnosis of clinically insignifi cant cancer and are better able to identify higher risk. In the longer-term, we acknowledge that the volume and type of patients being referred to secondary care could change depending on future validation of potential screening strategies that incorporate risk calculators and biomarkers. 39 Men in PROMIS have consented to followup through linkage to central registries for mortality and cancer outcomes so long-term outcomes can be ascertained.
Cost-eff ectiveness analyses of the PROMIS data are underway and will be reported elsewhere, but the primary outcome data provide a strong argument for recommending MP-MRI to all men with an elevated serum PSA before biopsy. Using MP-MRI as a triage test would reduce the problem of unnecessary biopsies in men who have a low risk of harbouring clinically signifi cant cancer, reduce the diagnosis of clinically insignifi cant disease and improve the detection of clinically signifi cant cancers.
In conclusion, TRUS-biopsy performs poorly as a diagnostic test for clinically signifi cant prostate cancer. MP-MRI, used as a triage test before fi rst prostate biopsy, could identify a quarter of men who might safely avoid an unnecessary biopsy and might improve the detection of clinically signifi cant cancer.
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